M. Sika

发表

Blood Pressure Control, Drug Therapy, and Kidney Disease

T. Greene, R. Toto, B. Wilkening, 2005, Hypertension.

Mechanisms of hyperinsulinemia and hyperglucagonemia after liver transplantation.

W. Chapman, P. Flakoll, Y. Becker, 1997, The Journal of surgical research.

Predictors of participant adherence and retention in the African American Study of Kidney Disease and Hypertension.

J. Charleston, Xuelei Wang, Deborah Brooks, 2008, Nephrology nursing journal : journal of the American Nephrology Nurses' Association.

Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials

D. Jalal, J. Dwyer, B. Greco, 2015 .

Pyridoxamine Dihydrochloride in Diabetic Nephropathy (PIONEER-CSG-17): Lessons Learned from a Pilot Study

J. Lewis, J. Dwyer, B. Greco, 2014, Nephron.

A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.

J. Lewis, R. Rodby, Y. Shyr, 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate.

J. Lewis, T. Greene, J. Wright, 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease.

Lawrence Appel, Tom Greene, Janice Lea, 2006, Journal of the American Society of Nephrology : JASN.

Original Investigation The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial

J. Lewis, T. Greene, M. Koury, 2015 .

The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.

J. Lewis, T. Greene, M. Koury, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Nitrogen metabolism at chronic low energy intakes

D. Layman, M. Sika, 1993 .

Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.

J. Lewis, M. Koury, M. Kaplan, 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs

J. Lewis, R. Rodby, J. Dwyer, 2015, Expert review of pharmacoeconomics & outcomes research.

Hepatic uptake of amino acids immediately after liver transplantation is well preserved despite altered plasma profiles.

W. Chapman, P. Flakoll, C. Pinson, 1998, The Journal of surgical research.

Neurocognitive Function Changes Following Kidney Transplant: A Prospective Study

J. Jackson, I. Feurer, R. Forbes, 2022, Kidney Medicine.

The Safety and Tolerability of Ferric Citrate as a Phosphate Binder in Dialysis Patients

J. Lewis, T. Greene, M. Koury, 2012, Nephron Clinical Practice.

Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness

J. Lewis, U. Bhatt, S. Fadem, 2015, Therapeutic advances in chronic disease.

Rationale and study design of a three‐period, 58‐week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis

J. Lewis, M. Koury, G. Schulman, 2013, Hemodialysis international. International Symposium on Home Hemodialysis.

WAGR Syndrome: A Clinical Review of 54 Cases

Bernard V Fischbach, Kelly L Trout, Julia Lewis, 2005, Pediatrics.

Net hepatic glucose output is normal on postoperative day 1 after liver transplantation.

W. Chapman, P. Flakoll, Y. Becker, 1998, The American surgeon.

Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort.

J. Lewis, T. Greene, R. Toto, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data

J. Lewis, R. Rodby, J. Dwyer, 2015, Drugs in R&D.

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

J. Lewis, T. Greene, M. Koury, 2015, Journal of the American Society of Nephrology : JASN.

Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

J. Lewis, T. Greene, M. Koury, 2015, Journal of the American Society of Nephrology : JASN.

292 A Dose-Ranging and Efficacy Phase 3 Trial of Ferric Citrate (FC) as a Phosphate Binder in Dialysis Patients

J. Lewis, M. Kaplan, G. Schulman, 2011 .

286: Iron Absorption With Higher Doses of Ferric Citrate in Controlling Serum Phosphorus in ESRD Patients

J. Lewis, T. Greene, S. Korbet, 2010 .

287: The Safety and Tolerability of Higher Doses of Ferric Citrate (FC) in Controlling Serum Phosphorus (P) In ESRD Patients

J. Lewis, T. Greene, S. Korbet, 2010 .

Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study.

L. Appel, T. Erlinger, J. Lewis, 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis

J. Lewis, T. Greene, D. Jalal, 2017, Hemodialysis international. International Symposium on Home Hemodialysis.

BP Control and Long-Term Risk of ESRD and Mortality.

L. Appel, G. Bakris, D. Glidden, 2017, Journal of the American Society of Nephrology : JASN.

Disparate Estimates of Hypertension Control From Ambulatory and Clinic Blood Pressure Measurements in Hypertensive Kidney Disease

Mahboob Rahman, L. Appel, T. Greene, 2009, Hypertension.

A model for the extended studies of hepatic hemodynamics and metabolism in swine.

C. Pinson, J. K. Wright, P. Williams, 1996, Laboratory animal science.

Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.

T. Greene, M. Unruh, J. Kusek, 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis .

J. Lewis, T. Greene, M. Koury, 2017, Clinical nephrology.

Clinical Practice: Original Paper Pyridoxamine Dihydrochloride in Diabetic Nephropathy (pioneer-csg-17): Lessons Learned from a Pilot Study

J. Dwyer, M. Sika, K. Umanath, 2022 .